Evidence map›Paper›PMID 23333145›Full record

ArticleJournal of the American College of Cardiology2013

Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort.

Alexandre Mebazaa, Etienne Gayat, Johan Lassus, Taly Meas, Christian Mueller, Aldo Maggioni, Frank Peacock, Jindrich Spinar, Veli-Pekka Harjola, Roland van Kimmenade and 18 more

2 registry-linked trialsOpen access · greenAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of the American College of Cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 48 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 3 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04298229 phase3completedstarted 2020, after this paper: background citation

A Randomized, Open-label Study of Dapagliflozin in Patients With or Without Type 2 Diabetes Admitted With Acute Heart Failure

Ran2020Enrolled240Registered outcomes3Posted comparisons0ConditionsDiabetes Mellitus, Type 2, Heart FailureArmsDapagliflozin 10 mg, Protocolized Diuretic Therapy
Open the trial in the graph
NCT03048032 completednot on this mapstarted 2015, after this paper: background citation

Diagnostic and Prognostic Value of Cardiac Biomarkers and Echocardiography for Patients Hospitalized Due to Acute Dyspnea: Prospective Observational Multicenter Cohort Study

TypeobservationalSponsorVilnius UniversityRan2015 to 2018Enrolled1,566ConditionsAcute Heart FailureArmsBlood sampling, Echocardiography exam
3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 18 institutions in 12 countries.

Alexandre MebazaaDepartment of Anesthesiology and Intensive Care, Lariboisière University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, Paris, France. alexandre.mebazaa@lrb.aphp.fr
Etienne Gayat
Johan Lassus
Taly Meas
Christian Mueller
Aldo Maggioni
Frank Peacock
Jindrich Spinar
Veli-Pekka Harjola
Roland van Kimmenade
Atul Pathak
Thomas Mueller
Luigi Tavazzi
Salvatore Disomma
Marco Metra
Domingo Pascual-Figal
Said Laribi
Damien Logeart
Semir Nouira
Naoki Sato
Jiri Parenica
Nicolas Deye
Riadh Boukef
Corinne Collet
Greet Van den Berghe
Alain Cohen-Solal
James L Januzzi
GREAT Network
Inserm · FRDélégation Paris 7 · FRHelsinki University Hospital · FIMasaryk University · CZAssociazione Nazionale Medici Cardiologi Ospedalieri · ITAzienda Ospedaliera Sant'Andrea · ITCleveland Clinic · USConvent Hospital of the Brothers of Saint John of God · ATHarvard University · USHospital Fatuma Bourguiba Monastir · TNHospital Universitario Virgen de la Arrixaca · ESKU Leuven · BEMaria Cecilia Hospital · ITNippon Medical School Musashi Kosugi Hospital · JPUniversité Fédérale de Toulouse Midi-Pyrénées · FRUniversity Hospital of Basel · CHUniversity Medical Center Utrecht · NLUniversity of Brescia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this analysis was to assess the association between elevated blood glucose level and mortality in acute heart failure (AHF).

backgroundElevated blood glucose has been reported to be prognostically meaningful in patients with cardiac diagnoses, such as coronary artery disease. The short-term prognostic impact of hyperglycemia in AHF is unknown, however.

methodsIn a multinational cohort of AHF, we examined the ability of blood glucose concentrations at presentation to predict all-cause mortality by 30 days. Fully adjusted models for prognosis included a previous diagnosis of diabetes mellitus as a covariate.

resultsA total of 6,212 subjects with AHF (mean age, 72 years; 52.5% male) were studied; the median blood glucose concentration on arrival at the hospital was 7.5 mmol/l (135 mg/dl), and 41% had a previous diagnosis of diabetes mellitus (DM). After 30 days, 618 patients (10%) had died. Compared with survivors, decedents had significantly higher median blood glucose concentrations (8.9 mmol/l vs. 7.4 mmol/l; p < 0.0001). In the fully adjusted model, an elevated blood glucose level was an independent predictor of 30-day mortality in AHF (odds ratio: 2.19; 95% confidence interval: 1.69 to 2.83; p < 0.001). The risk associated with an elevated blood glucose level appeared consistent across all subgroups of patients, including patients with preserved (hazard ratio: 5.41; 95% confidence interval: 2.44 to 12.0; p < 0.0001) and impaired systolic function (hazard ratio: 2.37; 95% confidence interval: 1.57 to 3.59; p < 0.0001). Furthermore, in reclassification analyses, elevated blood glucose added significant prognostic information to clinical parameters alone (4.4% net reclassification improvement; p = 0.01).

conclusionsAmong patients with AHF, blood glucose concentrations at presentation are powerfully prognostic for 30-day mortality, independent of a diagnosis of diabetes mellitus or other clinical variables. Because blood glucose is easily modifiable, it may represent a valid target for therapeutic intervention.

Indexed as

Heart FailureVentricular Function, LeftAcute DiseaseAgedAged, 80 and overBlood GlucoseCohort StudiesConfidence IntervalsCoronary Artery DiseaseDiagnostic Tests, RoutineFemaleHumansHyperglycemiaMaleOdds RatioOutcome Assessment, Health CareBlood Glucose

Identifiers

PMID23333145
OpenAlexW2114242574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.